Staying abreast of emerging career trends is imperative to remain ahead of the curve. Cultivating…
Vanessa Sanchez24th January 2024
News & Events
Peter Kearney, Chief Operating Officer of Virdis Group At a time of unprecedented development, the…
marknorm12th June 2023
VirdisGroup is pleased to announce that we will be attending Bio International Conference, which will take place…
marknorm16th May 2023
The life sciences industry is one of the world's most dynamic and rapidly evolving fields.…
marknorm2nd May 2023
VirdisGroup is pleased to announce that we will be attending LSX World Congress, which will take…
marknorm27th April 2023
VirdisGroup is pleased to announce that we will be attending Swiss Biotech Day, which will take…
marknorm31st March 2023
VirdisGroup, global specialists in Life Science Executive Search, is pleased to announce the appointment of…
marknorm17th March 2023
VirdisGroup is pleased to announce that we will be attending the BIO-Europe Spring Conference, which will…
marknorm9th March 2023
VirdisGroup, global specialists in Life Science Executive Search, is pleased to announce the appointment of…
marknorm8th March 2023
News
News | PharmaTimes
- Antag Therapeutics secures €80 million in weight loss therapy financing 4th December 2024Versant Ventures leads investment round to advance drug
- Everest therapy shows promise in nephropathy trial 4th December 2024Data highlights effectiveness of EVER001 in treating pMN
- KIMMTRAK recommended for funding by NICE for uveal melanoma patients 3rd December 2024Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for Health and Care Excellence (NICE) and is now available through the NHS. This marks a significant reversal of last year’s negative decision, allowing the first treatment shown to prolong survival in HLA-A*02:01-positive adults with metastatic or unresectable […]
- Orbit Discovery and Evergreen Theragnostics expand research collaboration 3rd December 2024Partnership aims to develop new radiopharmaceuticals for cancer treatment
- OGT launches enhanced genetic profiling panel for CLL 2nd December 2024New SureSeq CLL + CNV V3 panel improves understanding of CLL